Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.
Performance of psychedelic public companies this past week.
Cybin ($CYBN) entered into an agreement to acquire a Phase I DMT study from Entheon Biomedical and received Institutional Review Board approval to begin the first-in-human Phase I/IIa clinical trial evaluating CYB003, their proprietary deuterated psilocybin analog, as a potential treatment of major depressive disorder. Details
Tryp Therapeutics ($TRYP | $TRYPF) provided initial data from their Phase II clinical trial focused on psilocybin as a potential treatment for binge eating disorder. The first patient in the trial exhibited reduced overall anxiety; reduced anxiety around food; reduced compulsion to overeat; and improved self-image and confidence. Press Release
PharmaTher ($PHRM | $PHRRF) announced positive results evaluating the impact of KETABET for subjects with depression. The Study’s data support the benefit of pre-treatment to help reduce some or all of the unwanted side effects of ketamine therapy. Press Release
Nova Mentis Life Science ($NOVA | $NMLSF) received controlled substances export approval from the DEA for their proprietary psilocybin drug (NM-1001). Nova Mentis' psilocybin will be used to formulate microdose capsules for a planned Phase IIa fragile X syndrome clinical study. Press Release
Optimi Health ($OPTI | $OPTHF) entered into a supply agreement with ATMA Journey Centers, the first ever privately owned clinic in Canada to facilitate psilocybin assisted therapy under a Health Canada exemption. Optimi Health will supply psilocybin to ATMA for future therapist initiatives and supply requirements. Press Release
Filament Health ($FH | $FLHLF) cultivated their 70th variety of psilocybin-containing mushrooms at their GMP-compliant facility. Filament also announced the successful development of standardized, pharmaceutical-grade ayahuasca extract, designed for oral administration by capsule or tablet. Press Release
Clearmind Medicine ($CMND | $CMNDF) provided initial positive results for the treatment of cocaine addiction using MEAI, Clearmind's novel psychedelic molecule. The results of this research show potential for the first dedicated cocaine addiction treatment. Press Release
Nirvana Life Sciences ($NIRV) filed a new provisional patent application containing new claims for extraction and methods for use of Psilocybin as a treatment option for opioid addiction and relapse. Press Release
The Times Tribune: Pa. Veterans Will Help Study Psychedelic Drugs To Treat Trauma
The Economist: Bosses Want To Feed Psychedelics To Their Staff
New Haven Register: Psychedelics Show Promise For Depression, OCD, Yale Researchers Say
Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.